News | September 15, 2014

Beaumont First in Michigan to Test Gene-Directed Prevention Treatment for AFib

Research study to test new drug for prevention of atrial fibrillation in those with heart failure

September 15, 2014 — A new gene-directed drug being tested through a research study called GENETIC-AF may improve care, quality of life and survival in patients with heart failure and atrial fibrillation (AF). The Beaumont Health System in metropolitan Detroit is one of the study sites participating in the research. A previous study showed the drug being evaluated, called bucindolol hydrochloride, reduced symptomatic AF when compared with placebo in patients with a specific gene variation, or genotype. In the current study, bucindolol, a betablocker, is being compared with another betablocker called metoprolol succinate, a heart failure drug approved by the U.S. Food and Drug Administration (FDA).

“This is an important study of personalized medicine,” said David Haines, M.D., director of Beaumont’s Heart Rhythm Center and the study’s principal investigator. “One of the challenges in the treatment of AF in patients with heart failure is that we sometimes need to try many different drugs in a trial and error fashion to find out what’s going to work. By doing genetic testing, we’ll be able to identify those patients who may get an optimal response to this new drug.”

About half of the U.S. population is believed to have the specific gene variation that responds to bucindolol in the suppression and prevention of AF.

Beaumont is first in Michigan to participate in this national multicenter study, which will ultimately involve about 200 patients at about 50 centers in the United States and Canada in its first phase. Haines serves on the steering committee overseeing the study’s design and results.

Patients who are candidates for the study will first receive genetic screening through a blood draw to determine if they have the genetic marker, which has previously indicated a potential response to the drug. If they meet eligibility criteria, patients will be randomly assigned to one of two treatment groups to receive either the new study drug bucindolol or the drug metoprolol, which is approved for the treatment of heart failure but not for the prevention of atrial fibrillation. Study participation will last a minimum of six months, or up to four years.

“We’re hopeful that the GENETIC-AF study is going to identify new strategies and new medications to improve quality of life and survival in patients with heart failure and AF,” said Haines.

For more information:

Related Content

FDA Clamps Down on Unapproved Stem Cell Therapies
News | Stem Cell Therapies | December 20, 2018
December 20, 2018 — The U.S.
Secant Introduces First Synthetic Regenerative Cardiovascular Graft for CABG
News | Stem Cell Therapies | January 17, 2018
Secant Group, in partnership with its sister company SanaVita Medical, announced new technology to advance...
News | Stem Cell Therapies | October 24, 2017
October 24, 2017 — Roche and Ncardia have reached a broad licensing agreement whereby Roche and its affiliate compani
BioCardia Announces 12-Month Results from TRIDENT Trial of Stem Cell Delivery System
News | Stem Cell Therapies | September 26, 2017
BioCardia Inc. recently announced 12-month results from the Phase II TRIDENT clinical trial, conducted by the...
New Jersey Researcher Exploring New Stem Cell Therapies for Heart Attacks
News | Stem Cell Therapies | August 04, 2017
In petri dishes in her campus laboratory at New Jersey Institute of Technology, Alice Lee is developing colonies of...

An example of porcine cartdiac stem cells. Photo from the University of Miami Miller School of Medicine.


News | Stem Cell Therapies | June 12, 2017
June 12, 2017 — Heart muscle is one of the least renewable tissues in the body, which is one of the reasons that hear
Stem Cell Therapy Holds Promise for Treating Most Severe Cases of Angina
News | Stem Cell Therapies | May 12, 2017
An analysis of data from the entire development program consisting of three trials assessing the feasibility of using a...
3-D Printed Patch Can Help Mend a ‘Broken’ Heart

This photo shows the 3D-bioprinted cell patch in comparison to a mouse heart. When the patch was placed on a live mouse following a simulated heart attack, the researchers saw significant increase in functional capacity after just four weeks. Image courtesy of Patrick O’Leary, University of Minnesota.

News | Stem Cell Therapies | April 18, 2017
April 18, 2017 — A team of biomedical engineering researchers, led by the University of Minnesota, has created a revo
Texas Heart Institute, ischemic heart failure, adult stem cell therapy, CONCERT-HF clinical trial
News | Stem Cell Therapies | February 03, 2017
Physicians and researchers at Texas Heart Institute are recruiting patients who suffer from heart failure to...
Overlay Init